Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium, quantity: 28.284 mg/ml (equivalent: phenoxymethylpenicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: sucrose; sodium benzoate; saccharin sodium; colour; flavour - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms such as penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea. for the prevention of bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: mannitol; tribasic sodium phosphate dodecahydrate - short-term use where oral therapy is not appropriate for: 1.symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ?duodenal ulcer ?gastric ulcer ?reflux oesophagitis ?gastrointestinal lesions refractory to h2 blockers ?zollinger-ellison syndrome,2.maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.,note. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory drugs, whether on first presentation or recurrence.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - solution, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae,staphylococcus aureus and streptococcus pneumoniae

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tropisetron hydrochloride, quantity: 5.65 mg (equivalent: tropisetron, qty 5 mg) - injection, solution - excipient ingredients: acetic acid; sodium acetate trihydrate; sodium chloride; water for injections - ? for the prevention of nausea and vomiting induced by cytotoxic therapy (5mg/5ml ampoule only).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tropisetron hydrochloride, quantity: 2.26 mg (equivalent: tropisetron, qty 2 mg) - injection, solution - excipient ingredients: acetic acid; sodium acetate trihydrate; sodium chloride; water for injections - ? for the treatment and prevention of post-operative nausea and vomiting in adults (2mg/2ml ampoule only).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.988 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid; sodium citrate; sodium chloride; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.977 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftriaxone sodium -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 1.048 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.